Troy– Author –
-
WuXi Biologics Shanghai Drug Product Facility Achieves GMP Release, Expands Global Capacity
Contract Pharma China Overview WuXi Biologics' Drug Product Facility 15 (DP15) in Shanghai secured Good Manufacturing Practice (GMP) release in April 2026, becoming its 18th operational drug product facility globally. This state-of-the-a... -
FDA Approves Hepcludex, First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
FDA (Press Release), European AIDS Treatment Group USA Overview The U.S. FDA has approved Hepcludex (bulevirtide-gmod) injection as the first treatment for chronic hepatitis delta virus (HDV) infection in adults, with or without compensa... -
Tuning siRNA Packing Order in Lipid Nanoparticles Controls Oligonucleotide Functional Delivery
bioRxiv (Preprint) International Overview This preprint investigates how tuning the siRNA packing order within lipid nanoparticles (LNPs) can modulate oligonucleotide functional delivery, addressing a key challenge in RNA therapeutics: e... -
Insilico Medicine and Saudi Aramco Unveil ‘Sanity Pipeline’ for AI-Driven MOF Discovery
Insilico Medicine (Press Release), ChemRxiv (Preprint reference) Hong Kong Overview Insilico Medicine and Saudi Aramco have introduced the "Sanity Pipeline," an innovative AI-driven tool designed to tackle structural validity challenges ... -
CVS Caremark Expands Access to Eli Lilly’s Obesity Portfolio: Reinstates Zepbound, Adds Foundayo
FirstWord Pharma USA Overview CVS Caremark announced it will reinstate coverage for Eli Lilly's injectable weight-loss medication Zepbound (tirzepatide) and add the newly launched oral GLP-1 drug Foundayo (orforglipron) to its standard c... -
Daiichi Sankyo Unveils Extensive Oncology Portfolio Progress at ASCO; Datopotamab Deruxtecan Approved for First-Line mTNBC
Daiichi Sankyo (Press Release), MedCity News, ADC Review, FirstWord Pharma Japan Overview Daiichi Sankyo will present over 25 abstracts at the 2026 ASCO Annual Meeting, showcasing its leading oncology portfolio, including new clinical da... -
Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company (PRNewswire), Healthline, BioPharma Dive, The Guardian, BioSpace, GlobalData USA Overview Eli Lilly's triple hormone receptor agonist, retatrutide (GIP, GLP-1, and glucagon), demonstrated powerful and clinically mea... -
Key FDA Approvals Anticipated for GLP-1 Pipeline in May 2026 Update
Prime Therapeutics - Portal USA Overview Four significant FDA approval decisions for GLP-1 related medications are expected in 2026, marking critical advancements in metabolic disease management. Eli Lilly's injectable Mounjaro is antici... -
Eli Lilly Seals Landmark $2.75 Billion AI Drug Discovery Alliance with Insilico Medicine
IntuitionLabs, TipRanks, Tech Funding News USA Overview Pharmaceutical giant Eli Lilly has forged a strategic drug discovery and development collaboration with AI biotech pioneer Insilico Medicine, valued at up to $2.75 billion. The deal... -
European Biotechs Drive Next-Gen Cell & Gene Therapy Manufacturing Innovation
BioSpace UK Overview European biotechnology firms are making significant strides in cell and gene therapy (CGT) manufacturing, focusing on scalability and automation. UK-based Oxford Biomedica, a leading viral vector CDMO, specializes in...
